Ascendis Pharma A (ASND) Consolidated Net Income: 2014-2025
Historic Consolidated Net Income for Ascendis Pharma A (ASND) over the last 12 years, with Sep 2025 value amounting to -$62.8 million.
- Ascendis Pharma A's Consolidated Net Income rose 41.10% to -$62.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$236.4 million, marking a year-over-year increase of 47.15%. This contributed to the annual value of -$409.2 million for FY2024, which is 21.00% up from last year.
- Latest data reveals that Ascendis Pharma A reported Consolidated Net Income of -$62.8 million as of Q3 2025, which was down 78.17% from -$35.3 million recorded in Q2 2025.
- In the past 5 years, Ascendis Pharma A's Consolidated Net Income registered a high of -$35.3 million during Q2 2025, and its lowest value of -$200.7 million during Q4 2022.
- In the last 3 years, Ascendis Pharma A's Consolidated Net Income had a median value of -$106.7 million in 2024 and averaged -$101.0 million.
- In the last 5 years, Ascendis Pharma A's Consolidated Net Income tumbled by 85.96% in 2022 and then surged by 69.93% in 2025.
- Quarterly analysis of 5 years shows Ascendis Pharma A's Consolidated Net Income stood at -$121.3 million in 2021, then plummeted by 65.42% to -$200.7 million in 2022, then spiked by 59.64% to -$81.0 million in 2023, then surged by 52.12% to -$38.8 million in 2024, then skyrocketed by 41.10% to -$62.8 million in 2025.
- Its Consolidated Net Income stands at -$62.8 million for Q3 2025, versus -$35.3 million for Q2 2025 and -$99.5 million for Q1 2025.